UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2021
Commission File Number: 333-231839
CHINA SXT PHARMACEUTICALS, INC.
(Translation of registrant’s name into English)
178 Taidong Rd North, Taizhou
Jiangsu, China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Submission of Matters to a Vote of Security Holders.
The Company held its annual meeting of shareholders for its fiscal year ending March 31, 2021 at 9:30 a.m. ET on March 31, 2021 at its principal executive offices in Jiangsu China. Holders of 5,195,424 of the Company's ordinary shares were present in person or by proxy at the annual meeting, representing approximately 33.49% of the total 15,514,398 outstanding ordinary shares and therefore constituting a quorum of more than 33.33% of the shares outstanding and entitled to vote at the annual meeting as of the record date of February 22, 2021. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:
1. | Election of Directors |
The following individuals were elected as directors to serve on the Board of Directors (the “Board”) until the annual meeting of shareholders for the year ended Mach 31, 2022 or until his successor is duly elected and qualified. No broker non-votes are counted.
Director’s Name | For | Withheld | ||
Feng Zhou | 5,195,424 | 0 | ||
Jun Zheng | 5,195,424 | 0 | ||
Junsong Li | 5,195,424 | 0 | ||
Xiaodong Ji | 5,195,424 | 0 | ||
Wenwei Fan | 5,195,424 | 0 |
2. | Ratification of ZH CPA, LLC. as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2021 |
The shareholders ratified the appointment of ZH CPA, LLC as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2021. No broker non-votes are counted.
For | Against | Abstain | ||
5,195,424 | 0 | 0 |
3. | Approval of the Company’s 2021 Equity Incentive Plan. |
The shareholders approved the proposal. The Company’s 2021 equity incentive plan was declared effective immediately. No broker non-votes are counted.
For | Against | Abstain | ||
5,195,424 | 0 | 0 |
1
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENT
This Current Report contains forward-looking statements. All statements contained in this Current Report other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “seek” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Current Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, we undertake no duty to update any of these forward-looking statements after the date of this Current Report or to conform these statements to actual results or revised expectations.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHINA SXT PHARMACEUTICAL, INC. | ||
By: | /s/ Feng Zhou | |
Feng Zhou | ||
Chief Executive Officer |
Date: April 8, 2021
3